UNSPSC 51452405: Diethylcarbamazine citrate

This classification denotes an antihelminthic agent with the molecular formula C10H21N3O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OS1Z389K8S, chemically known as 4-methyl-n,n-bis(4-methylpiperazin-2-yl)-piperazine-1-carboxamide but more generally known as diethylcarbamazine citrate, which bears US NIH Compound Identifier 3052. European Medicines Agency schedules Diethylcarbamazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01686MIG.

UNSPSC 51452405 Diethylcarbamazine citrate is a Commodity code that in recent state and local procurement shows minimal relevance to its nominal scope. The recent opportunities tagged to this code—naloxone and drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals through cooperative purchasing—represent broader pharmaceutical and medical supply procurement rather than diethylcarbamazine citrate specifically. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance with participating Oregon entities). The Tampa procurement is designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5% bid discount.

Geographic activity is concentrated in Florida, Texas, Minnesota, and Oregon based on recent postings. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with a response date of July 26, 2026; the City of Tampa's ITB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a due date of March 13, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities with a response date of March 26, 2026. The code exhibits a mismatch between its specific pharmaceutical designation and the actual procurement activity captured under it, suggesting either taxonomy miscoding in source records or opportunistic use of a narrow code to represent broader pharmaceutical and medical supply categories.